[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn46-48;54
[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn36;37
[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn46;48;54;55
[2]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2005/209246,2005,A1Locationinpatent:Page/Pagecolumn35;36;37;39
[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2007/155702,2007,A1Locationinpatent:Page/Pagecolumn12
[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-US2007/155702,2007,A1Locationinpatent:Page/Pagecolumn12
Title: Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects.
Journal: The Journal of infectious diseases 20121001
Title: Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507.